Vivaxim Description

The dual-chamber syringe contains 0.5 millilitre of inactivated hepatitis A vaccine and 0.5 millilitre of typhoid polysaccharide vaccine which are mixed prior to administration.
After reconstitution, 1 dose (1 mL) contains: Originally contained in the suspension: Hepatitis A virus, GBM strain (inactivated)^1,2 160 U³.
¹ Produced in human diploid (MRC-5) cells.
² Adsorbed on aluminium hydroxide hydrated (0.3 milligram Al).
³ In the absence of an international standardised reference, the antigen content is expressed using an in-house reference.
Originally contained in the solution: Salmonella typhi (Ty2 strain) capsular Vi polysaccharides 25 micrograms.
The inactivated hepatitis A vaccine is a cloudy and whitish suspension; the typhoid polysaccharide vaccine is a clear and colourless solution.
Excipient(s) with known effect (see Precautions): Phenylalanine 10 micrograms.
Excipients/Inactive Ingredients: Inactivated hepatitis A vaccine components: 2-Phenoxyethanol Ethanol Formaldehyde, Medium 199 Hanks (without phenol red)* supplemented with polysorbate 80.
*Medium 199 Hanks (without phenol red) is a complex mixture of amino acids (including phenylalanine), mineral salts (including potassium), vitamins and other components (including glucose), diluted in water for injections and pH adjusted with hydrochloric acid or sodium hydroxide.
Typhoid Vi polysaccharide vaccine components: Phosphate buffer solution: Sodium chloride, Disodium phosphate dihydrate, Sodium dihydrogen phosphate dihydrate, Water for injections.
VIVAXIM may contain traces of neomycin, which is used during the manufacturing process (see Contraindications).